AIP
DYN icon

Arrowpoint Investment Partners’s Dyne Therapeutics DYN Stock Holding History

Arrowpoint Investment Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,213
Closed -$312K – 138
2026
Q1 		$312K Buy
17,213
+2,830
+20% +$48.8K 0.28% 56
2025
Q4 		$281K Buy
+14,383
New +$272K 0.04% 88

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arrowpoint Investment Partners's DYN Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 17,213 shares — an estimated $312K sold.

Arrowpoint Investment Partners first reported a position in DYN in Q4 2025 and held it in 2 quarters. The position peaked at $312K in Q1 2026. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 17,213 Dyne Therapeutics shares in Q2 2026, an estimated $312K.
  • Arrowpoint Investment Partners first reported a position in Dyne Therapeutics in Q4 2025 and held it in 2 quarters.
  • Arrowpoint Investment Partners's Dyne Therapeutics position peaked at $312K in Q1 2026.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.